PCSK9 and diabetes mellitus: In subgroup analysis of each PCSK9 inhibitor, alirocumab treatment afforded a significant reduction in the risk of diabetes-related adverse events compared to control treatment (RR = 0.9137; 95% CI, 0.845–0.987) (Figure 3).